Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00715559 · ClinicalTrials.gov registry record · NA
Cysteamine Therapy for Major Depressive Disorder
A NA study, sponsored by Icahn School of Medicine at Mount Sinai.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT00715559: Clinical Trial NA study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT00715559 is a NA study that was terminated before completion, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00715559, a NA study, was terminated before completion, sponsored by Icahn School of Medicine at Mount Sinai.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether cysteamine bitartrate, an FDA-approved drug for a non-psychiatric condition, is safe and effective for the treatment of major depression.
Primary Outcome
This scale measures depression severity. It ranges from a score of 0 to 60, with higher score indicating higher level of depression severity.
Interventions
- DRUG cysteamine bitartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-05 |
| Phase | NA |
Why NCT00715559 stopped before completion
NCT00715559 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which cysteamine bitartrate is the first listed.
NCT00715559 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00715559 about?
NCT00715559 is a clinical study titled "Cysteamine Therapy for Major Depressive Disorder". The purpose of this study is to determine whether cysteamine bitartrate, an FDA-approved drug for a non-psychiatric condition, is safe and effective for the treatment of major depression.
What is the current status of trial NCT00715559?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2008-07. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00715559?
The interventions under investigation include: cysteamine bitartrate (DRUG).
Who is sponsoring clinical trial NCT00715559?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00715559's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia